logo-loader
RNS
Biodexa Pharmaceuticals PLC

Midatech Pharma PLC - Director/PDMR Shareholding

RNS Number : 3827S
Midatech Pharma PLC
20 December 2016
 

 

 

 

20 December 2016

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Director/PDMR Shareholding

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, announces that today, 20 December 2016, certain PDMRs purchased ordinary shares of 0.005p each in the capital of the Company ("Ordinary Shares"). Details of the purchases and the effect on the PDMRs' beneficial holding in the Company are given below. Additionally, on 19 December 2016, Jim Phillips, Chief Executive Officer and a PDMR, gifted Ordinary Shares to certain adult members of his family by way of transfer for nil consideration, details of which are also given below.

 

PDMR

Number of Ordinary Shares purchased

Purchase price per Ordinary Share

Number of Ordinary Shares transferred to adult members of family

Consideration per Ordinary Share of transfer

Resulting beneficial interest in Ordinary Shares

Resulting beneficial interest in the Company as a % of share capital

Jim Phillips, CEO

13,380

110p

7,900

Nil

46,896

0.096%

Craig Cook, CSO

2,000

110p

-

-

2,000

0.004%

 

 

- Ends -

 

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Cameron Standage

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Notes for Editors

 

About Midatech Pharma PLC

 

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a US commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and our proprietary gold nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.110 staff in four countries. For further company information see: www.midatechpharma.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLBLFLQLFEFBZ
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read